-80%

est. 2Y upside i

HealthcareAI & MLSeed

We develop frontier AI systems that identify biological threats and design medical countermeasures in real time. Our founding team comes from Palantir, DeepMind, the Broad Institute, and the Arc Institute.

Rank

#1439

Sector

Biotechnology, AI/Biodefense Software

Est. Liquidity

~5Y

Data Quality

Data: Medium

This opportunity presents a high-risk, high-reward profile, driven by a compelling mission and strong AI expertise, but significantly challenged by dominant incumbents with deep government ties in a highly regulated sector.

Last updated: February 16, 2026

Bull (25%)+400%

Valthos rapidly secures multiple significant government contracts and demonstrates a clear, superior advantage in real-time threat identification and countermeasure design, leading to a substantial Series A/B round or early strategic acquisition.

Base (25%)+50%

Valthos makes steady progress on product development and secures initial smaller contracts, but faces strong competition from incumbents and slower-than-expected market penetration.

Bear (50%)-90%

Valthos struggles to overcome regulatory hurdles, fails to secure meaningful contracts against established players like Gingko Bioworks, or its technology proves insufficient to gain a significant market foothold, leading to a down round or failure.

Est. time to liquidity~5.0 years
View all 3 open roles at Valthos →

Last updated: March 10, 2026

Community

Valuation Sentiment

Our model estimates -80% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.